|October 18, 2001|
Taisho launches Menfula Hap [IM] :
Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) has announced the release of Menfula Hap [IM], which was formulated with the anti-inflammatory and analgesic ingredient, indomethacin, on October 22, 2001.
Menfula Hap [IM] is the first indomethacin-formulated warming-Sensation poultice to be sold as an over-the-counter drug in Japan. The adoption of indomethacin, which has been highly praised in medical circles for its analgesic properties, and a steadily progressing warming sensation make the new product highly effective against stiff and sore shoulders, and backaches.
It is said that more than 10 million Japanese men and women suffer from stiff shoulders, one of the most serious problems facing office workers, and backaches, the unavoidable fate of upright-walking humankind. Especially in the winter season, as cold temperatures contract muscles, causing poor blood circulation, the number of those who suffer from stiff shoulders and backaches increases.
Menfula Hap [IM] is an anti-inflammatory and analgesic poultice especially recommended to those who suffer from chronic stiff shoulders and backaches. It combines the effects of pain killing through indomethacin's superior anti-inflammatory and analgesic actions, and muscular tension relief through the slow warming sensation.